Analyst Price Target is $48.33
▲ +6.93% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Scholar Rock in the last 3 months. The average price target is $48.33, with a high forecast of $53.00 and a low forecast of $42.00. The average price target represents a 6.93% upside from the last price of $45.20.
Current Consensus is
Buy
The current consensus among 16 polled investment analysts is to buy stock in Scholar Rock. This Buy consensus rating has held steady for over two years.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More
